B4 Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Aktana provides a real-time orchestration platform for pharmaceutical marketing that coordinates digital and field engagement across channels to reach healthcare professionals at optimal times.
AI & Machine LearningEnterprise SoftwareSales TechSan Francisco, US
David J. Ehrlich(Executive Officer, Director)Derek Choy(Executive Officer, Director)Jin Huang(Executive Officer)Rob Willson(Executive Officer)Marc-david Cohen(Executive Officer)
BoardAnthony Glenning(Director)
Board seatRobert Mittendorff· per SEC Form D · $30M raise · filed Oct 2020
Co-investorsHLM Venture PartnersNorwest Venture PartnersStarfish VenturesTRANSFORMATION CAPITALUpfront Ventures
Atomwise uses artificial intelligence and machine learning to discover novel small-molecule drugs, with a current focus on developing treatments for immune and inflammatory diseases.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Izhar Wallach(Executive Officer, Director)inAbraham Heifets(Executive Officer, Director, Promoter)Yan Zhao(Executive Officer)Stephen Worland(Executive Officer, Director)
BoardRobert Mittendorff(Director)inAdam Seabrook(Director)in
Board seatRaj Ganguly· per SEC Form D · $127M raise · filed Aug 2020
Co-investorsAurum Venture PartnersB Capital GroupCerity Partners VenturesCreative Destruction Lab (CDL)Draper AssociatesThreshold Ventures+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.